# Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children

> **NCT02455921** · PHASE4 · COMPLETED · sponsor: **Attikon Hospital** · enrollment: 200 (actual)

## Conditions studied

- Anesthesia; Functional

## Interventions

- **DRUG:** neostigmine - atropine
- **DRUG:** Sugammadex

## Key facts

- **NCT ID:** NCT02455921
- **Lead sponsor:** Attikon Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2018-03
- **Final completion:** 2018-04
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02455921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02455921, "Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02455921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*